In the present study, we explored the rechallenge strategy with cetuximab-based therapy in clinically and molecularly selected, heavily pretreated (i.e., 92.3% received rechallenge with anti-EGFR in fourth- or fifth-line therapy) colorectal cancer patients. Here, EGFR is linked to colorectal cancer.